Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines.

OBJECTIVE Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and internal organs. Dysregulation of the immune system, including the Th1/Th2 cytokine balance, is central to the pathogenesis of SSc. This study was undertaken to investigate the hypothesis that single-nucleotide polymorphisms (SNPs) in TBX21 and STAT4, both of which are critical transcription factors that regulate the Th1/Th2 balance, are associated with SSc susceptibility. METHODS We tested SNPs in TBX21 and STAT4 for association with SSc in 2 independent cohorts, the SSc Registry cohort (880 SSc cases and 507 controls) and the University of Texas SSc cohort (522 cases and 531 controls). Additional white control genotypes were obtained from public repositories. We also investigated for gene-gene interactions. Plasma cytokines and whole blood gene expression profiles were examined to determine functional effects of these SNPs. RESULTS Multiple SNPs in TBX21 and STAT4 were found to be associated with SSc. In a combined analysis of 902 SSc patients and 4,745 controls, TT genotyping of the TBX21 rs11650354 variant revealed a recessive pattern for disease susceptibility (Pcorr=1.4x10(-15), odds ratio 3.37, 95% confidence interval 2.4-4.6). In an analysis of 1,039 SSc patients and 3,322 controls, the A allele of the STAT4 variant rs11889341 was associated with increased SSc susceptibility in a dominant pattern (Pcorr=2.4x10(-5), odds ratio 1.29, 95% confidence interval 1.2-1.5). Furthermore, we identified gene-gene interaction among the TBX21 and STAT4 variants, such that the STAT4 genotype increased the risk of SSc only in the TBX21 CC genotype group. SSc patients carrying the TBX21 CC genotype had higher interleukin-6 (IL-6) and tumor necrosis factor alpha levels, and those with the TT genotype had elevated IL-2, IL-5, IL-4, and IL-13 (Th2) levels, compared with controls. Whole blood expression profiles revealed dysregulation of type I interferon pathways in the CC group and T cell pathways in the TT group of the TBX21 SNP. CONCLUSION The present results, from studies of 2 independent cohorts, indicate that SNPs in TBX21 and STAT4 contribute uniquely and interactively to SSc susceptibility, leading to altered cytokine balance and immune dysregulation.

[1]  R. Scorza,et al.  The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. , 2009, Human molecular genetics.

[2]  M. Hudson,et al.  Scleroderma prevalence: demographic variations in a population-based sample. , 2009, Arthritis and rheumatism.

[3]  L. Glimcher,et al.  Restoration of T-box-containing protein expressed in T cells protects against allergen-induced asthma. , 2009, The Journal of allergy and clinical immunology.

[4]  S. Shim,et al.  Association of TBX21 polymorphisms in a Korean population with rheumatoid arthritis , 2009, Experimental & Molecular Medicine.

[5]  Ferdousi Chowdhury,et al.  Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. , 2009, Journal of immunological methods.

[6]  M. Zervou,et al.  STAT4: a risk factor for type 1 diabetes? , 2008, Human immunology.

[7]  F. Holsboer,et al.  IL 2 RA and IL 7 RA genes confer susceptibility for multiple sclerosis in two independent European populations , 2008 .

[8]  Geoffrey Hom,et al.  Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. , 2008, The New England journal of medicine.

[9]  F. Arnett,et al.  Genetics and genomic studies in scleroderma (systemic sclerosis). , 2008, Rheumatic diseases clinics of North America.

[10]  Wentian Li,et al.  STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. , 2007, The New England journal of medicine.

[11]  M. Mayes,et al.  An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis. , 2007, Rheumatology.

[12]  P. Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.

[13]  C. Szeto,et al.  Decreased T‐bet expression and changes in chemokine levels in adults with asthma , 2007, Clinical and experimental immunology.

[14]  L. Glimcher,et al.  Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13 , 2007, Proceedings of the National Academy of Sciences.

[15]  Minghua Wu,et al.  Increased Bleomycin-Induced Skin Fibrosis in Mice Lacking the Th1-Specific Transcription Factor T-bet , 2007, Pathobiology.

[16]  M. Mayes,et al.  Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. , 2006, Arthritis and rheumatism.

[17]  Zeny Z. Feng,et al.  Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. , 2006, Arthritis and rheumatism.

[18]  Xiaodong Zhou,et al.  Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. , 2006, Rheumatology.

[19]  Yuka Kanno,et al.  T-bet regulates Th1 responses through essential effects on GATA-3 function rather than on IFNG gene acetylation and transcription , 2006, The Journal of experimental medicine.

[20]  R. Millikan,et al.  Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. , 2006, American journal of human genetics.

[21]  Stephen B. Johnson,et al.  The New York cancer project: Rationale, organization, design, and baseline characteristics , 2004, Journal of Urban Health.

[22]  Gudmundur A. Thorisson,et al.  The International HapMap Project Web site. , 2005, Genome research.

[23]  P. Galle,et al.  Asthmatic changes in mice lacking T-bet are mediated by IL-13. , 2005, International immunology.

[24]  L. Settas,et al.  Early T cell activation in the skin from patients with systemic sclerosis , 2005, Annals of the rheumatic diseases.

[25]  J. Kere,et al.  Association analysis of common variants of STAT6, GATA3, and STAT4 to asthma and high serum IgE phenotypes. , 2005, The Journal of allergy and clinical immunology.

[26]  S. Weiss,et al.  TBX21: A functional variant predicts improvement in asthma with the use of inhaled corticosteroids , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Ihara,et al.  Identification of a novel type 1 diabetes susceptibility gene, T-bet , 2004, Human Genetics.

[28]  J. Kere,et al.  Association study of 15 novel single‐nucleotide polymorphisms of the T‐bet locus among Finnish asthma families , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[29]  H. Shin,et al.  Association analysis of novel TBX21 variants with asthma phenotypes , 2003, Human mutation.

[30]  S. Szabo,et al.  Development of Spontaneous Airway Changes Consistent with Human Asthma in Mice Lacking T-bet , 2002, Science.

[31]  T. Medsger,et al.  Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.

[32]  J. Reveille,et al.  Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. , 2001, Seminars in arthritis and rheumatism.

[33]  D. Milewicz,et al.  Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. , 2001, Arthritis and rheumatism.

[34]  M. Mayes.  The establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis , 2000, Current rheumatology reports.

[35]  Heping Zhang,et al.  Use of classification trees for association studies , 2000, Genetic epidemiology.

[36]  Laurie H Glimcher,et al.  A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment , 2000, Cell.

[37]  R. Scorza,et al.  Increased interferon‐gamma (IFN‐γ) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon , 1999, Clinical and experimental immunology.

[38]  J. Reveille,et al.  HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis). , 1999, Tissue antigens.

[39]  D. Milewicz,et al.  Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population. , 1998, Arthritis and rheumatism.

[40]  G. Pizzolo,et al.  Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. , 1997, The American journal of pathology.

[41]  M. Di Franco,et al.  Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease , 1997, Clinical and experimental immunology.

[42]  J. Reveille,et al.  Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. , 1996, Arthritis and rheumatism.

[43]  J. Reveille,et al.  Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. , 1996, Arthritis and rheumatism.

[44]  F. Arnett.  HLA and autoimmunity in scleroderma (systemic sclerosis). , 1995, International reviews of immunology.

[45]  N. Olsen,et al.  Anti‐centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study , 1994, Clinical and experimental immunology.

[46]  F. Wigley,et al.  Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. , 1992, Arthritis and rheumatism.

[47]  M. Kahaleh,et al.  Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. , 1989, Annals of internal medicine.

[48]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[49]  M. Fritzler,et al.  The CREST syndrome: a distinct serologic entity with anticentromere antibodies. , 1980, The American journal of medicine.

[50]  E. Tan,et al.  Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. , 1980, Arthritis and rheumatism.

[51]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[52]  E. Tan,et al.  Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. , 1979, The Journal of biological chemistry.